Rapid Waning of COVID Vaccine Requires Reevaluation of Future Booster Campaigns: Study

An Israeli health worker administers a dose of the Pfizer-BioNtech COVID-19 vaccine to a man, at the Maccabi Health Service in the Israeli town of Rishon Lezion, Israel, in August 2021. Ahmad Gharabli/AFP via Getty Images

An Israeli study has concluded that the short-lived immunity and rapid waning of the Pfizer BioNTech COVID-19 vaccine necessitates the reevaluation of future COVID-19 vaccination campaigns.

The authors said that while the vaccine was effective in decreasing morbidity and mortality, “its relatively small effect on transmissibility of Omicron … and its rapid waning call for reassessment of future booster campaigns.”